

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Scheller, D.  
Serial No.: 10/585,609  
Filed: 10 July 2006  
Title: USE OF SUBSTITUTED 2-AMINOTETRALINS FOR PREVENTIVE  
TREATMENT OF PARKINSON'S DISEASE  
Group Art Unit: 1614  
Examiner: S.M. Rao  
Confirmation No.: 7974  
Docket No.: 6102-000013/US/NP  
Client Ref.: P/Sche/V/9/03

**SUBMITTED ELECTRONICALLY VIA EFS-WEB**

**14 December 2009**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

REQUEST FOR CONTINUED EXAMINATION UNDER 37 C.F.R. §1.114  
(INCLUDING SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT UNDER  
37 C.F.R. §1.97(b)(4))

This paper is responsive to a final Office Action dated 14 September 2009 in the above referenced application, in which a shortened statutory period of three months was set for reply. Applicant hereby submits a Request for Continued Examination (RCE) under 37 C.F.R. §1.114, accompanied by an amendment and response to all remaining grounds of rejection. Authorization is further provided herewith to charge the RCE fee required under 37 C.F.R. §1.17(e) to Deposit Account No. 08-0750.

This response is timely submitted and no fee for extension of time is believed payable. Should any fee be found payable in respect of the present submission, authorization is hereby provided to charge such fee to Deposit Account No. 08-0750.

Applicant also submits herein a supplemental Information Disclosure Statement under 37 C.F.R. §1.97(b)(4).

Serial No. 10/585,609

6102-000013/US/NP

RCE, Amendment C, Response to Office Action dated 14 September 2009, and Supplemental IDS

14 December 2009

AMENDMENT UNDER 37 C.F.R. §1.114 (AMENDMENT C)

Further examination of the above referenced application is requested following entry of the present amendment.

Amendments IN THE CLAIMS are reflected in the listing of claims beginning on page 3 of this paper. Following amendment herein, the total number of claims previously paid for is not increased, therefore no excess claim fee is believed owed.

REMARKS on the present amendment begin on page 8 of this paper.

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT begins on page 23 of this paper.